TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* OIF/OEF veteran~* Between the ages of 18 and 50 years old~* Not taking medications known to affect sleep or wake function for 2 weeks~Additional selection criteria for PTSD subjects are:~* Trauma occurred three months or more before study entry~* Meeting diagnostic criteria for current PTSD according to the Clinician Administered PTSD Scale (CAPS)~* Participants will remain in ongoing counseling services~Additional selection criterion for non-PTSD healthy subjects:~* Not meet DSM-IV diagnostic criteria for current PTSD~* Have a total score \< 13 on the Beck Depression Inventory~* Participants who are active-duty military personnel will be required to obtain permission from their commander to participate in this study.~Exclusion Criteria:~* Current diagnosis of untreated, severe depression as determined by the Structured Clinical Interview for Diagnostic and Statistical Manual- IV Edition (DSM-IV), non-patient version~* Beck Depression Inventory \> 30~* History of psychotic or bipolar disorder~* Current history (within 3 months) of substance or alcohol abuse~* Significant or unstable acute or chronic medical conditions~* Other current sleep disorders~* Presence of implanted devices or metal in body such as cardiac pacemaker, aneurysm clip, ear implant, shrapnel, neurostimulators or other metal devices~* Fear of closed spaces~* Previous radiation exposure (past year) that exceeds recommended safety limits~* Pregnancy or breast feeding~* Resting blood pressure \< 90/60 at the screening physical examination~* Heart rate \> 100 beats/minutes~* Current use of a beta-blocker~* Use of an alpha-1 antagonist agent in the previous 3 weeks~* Refusal to follow the safety measures in the case of use of a phosphodiesterase 5 inhibitor (Cialis, Viagra, Levitra)~* Unexpected, untreated, or serious EKG findings

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Prazosin (Type: EXPERIMENTAL): Active medication arm. Prazosin is an FDA approved medication, originally designed as an anti-hypertension medication. Side effects of the medication in some include sleepiness and once asleep, sustained sleep.
- Placebo (Type: PLACEBO_COMPARATOR): A placebo is a sugar pill, which will be used to compare with the results of the active medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Hematoma Block on Postoperative Pain After Femoral Intramedullary Rodding: A Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Trauma patient at the University of Cincinnati Medical Center~* Skeletally mature patients~* Have an isolated, closed, acute traumatic femoral shaft fracture to be treated with a closed reduction and reamed intramedullary rod fixation~Exclusion Criteria:~* Unable to provide informed consent~* Member of a vulnerable patient population~* Have additional injuries~* Have a history of prior existing narcotic use or chronic pain management issues on presentation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hematoma block (Type: EXPERIMENTAL): Fracture site injection of 20 mL of 0.5% ropivacaine with an 18-gauge needle (150 mm length).
- Normal saline injection (Type: PLACEBO_COMPARATOR): Fracture site injection of 20ml of normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants must be postmenopausal (after the time in life when a woman stops having a menstrual period) or surgically sterile or if sexually active, practicing an effective method of birth control (e.g., oral contraceptive, intrauterine device \[IUD - an intrauterine device made of plastic and/or copper that is inserted into the womb \[uterus\] by way of the vaginal canal to used to prevent pregnancy\], diaphragm with spermicide \[agent that kills spermatozoa\] or condom \[cover worn over the penis during sexual intercourse to prevent infection or pregnancy\] with spermicide) throughout the study and have a negative serum beta - Human Chorionic Gonadotropin (HCG) pregnancy test at screening~* Participants on oral monotherapy (treatment with a single drug) with risperidone in a regimen within the daily dosage recommended by the package insert and adhering to the prescribed risperidone regimen for at least 30 days before entering the study~* Participants with partial response to the current risperidone regimen (persistent symptoms or unstable clinical condition) or presence of unbearable side effects~* Potential Participants switching to another atypical antipsychotic due to their clinical response and/or side effects profile.~Exclusion Criteria:~* Participants with past or current history of psychiatric disease other than schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV~* Participants with concomitant (given at the same time) severe (very serious, life threatening) medical or neurological disorder or risk of suicide~* Participants previously using clozapine~* Participants with a history of previous non-responsiveness to oral antipsychotic treatment~* Pregnant or breast-feeding female participants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone Extended Release (ER) (Type: EXPERIMENTAL): Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Proof of Concept Study of Serum Progesterone Levels for IVF/ICSI Following HCG Trigger for Oocyte Maturation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Females aged 18 to 42 years with regular menstrual cycles of 26-34 days~* Undergoing ovarian stimulation for IVF/ICSI \& PGS.~* Receiving recombinant FSH for stimulation~* hCG 5000iu IM as trigger injection for oocyte maturation.~* Ovarian stimulation in GnRH-antagonist protocols~* BMI 18- 35 kg/m2~* Having 1 or 2 euploid embryos for transfer in spontaneous natural cycles.~Exclusion Criteria:~* Poor ovarian reserve as defined by Bologna criteria~* PCOS in accordance with Rotterdam criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- stimulated cycles (Type: None): Patients will have blood drawn on five separate occasions: before and following hCG trigger on the day of final oocyte maturation and day of egg collection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 60 years to 75 years old~* Patients less than 60 years old, but with one or multiple high risk factors for esophageal cancer including smoking and drinking addiction,family history of esophageal cancer, personal history of esophageal or head and neck malignancies, previous endoscopy documenting iodine void superficial lesion.~Exclusion Criteria:~* Allergy to iodine or any other medicine which used in this trial.~* Previous endoscopy revealing advanced esophageal cancer or other non-superficial lesions.~* Conditions interfering visibility of endoscope including gastrointestinal obstruction and upper gastrointestinal bleeding.~* Anatomic variation by surgery.~* Pregnancy~* Other conditions which investigator consider the patient at high risk for complications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Pronase (Type: EXPERIMENTAL): Add pronase 20000 U in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
- control (Type: SHAM_COMPARATOR): No pronase in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Teenager between 12 and 18 years old; has either indoor tanned in the past year or has indicated their intentions to indoor tan in the coming year.~Exclusion Criteria:~* None other than not meeting inclusion criteria.

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Appearance-Focused Website Intervention (Type: EXPERIMENTAL): This is a Internet-based appearance-focused prevention intervention based on the Behavioral Alternatives Model.
- Control Website (Type: ACTIVE_COMPARATOR): Control participants viewed an Internet site designed to provide drug and alcohol education for teens.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women between 18 and 65, migraine must have occurred before the age of 50 years.~* Diagnosed migraine according to International Headache Society (IHS) criteria (ICHD-II)~Exclusion Criteria:~* Other neurological or neurodegenerative disorders~* Medical conditions that may interfere with the result - violent head trauma, stroke, transient ischemic attacks~* Musculoskeletal or mental illness~* Addictive or previous addictive behavior defined as the abuse of cannabis, opioids or other drugs~* Inability to cooperate~* Pregnancy or breastfeeding, including women trying to conceive~* Use of vitamin D supplementation\> 10μg~* In treatment with digoxin or thiazide~* Patients with osteoarthritis, as they are taking or have taken vitamin D supplements~* Patients with pre-existing hypercalcemia as vitamin D supplements are contraindicated in these patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D (Type: ACTIVE_COMPARATOR): The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.~The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.~D3 Vitamin ® consists of small white tablets, which are easy to swallow.~D3 Vitamin ® contains 25 micrograms vitamin D3 (colecalciferol) per tablet, equivalent to 1000 IU (International Units).~Tablet Excipients: Cellulose, dicalcium phosphate, magnesium stearate, silicon dioxide and talc. Vitamin D3 ® contains no gluten, soy, gelatin or other animal products.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets to match D3 Vitamin ®, were produced. They are identical to the D3 Vitamin ® in appearance, ie small white tablets. These tablets do not have a therapeutic effect. Placebo tablets produced and delivered by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of KHK7580

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Personally submitted written voluntary informed consent to participate in the study~* Stable chronic renal disease treated with peritoneal dialysis for at least 16 weeks before screening~* Intact PTH level of \> 240 pg/ml at screening~Exclusion Criteria:~* Treatment with cinacalcet hydrochloride within 2 weeks before screening;~* Change in dose or dosing regimen of an activated vitamin D drug or its derivative, phosphate binder, or calcium preparation within 2 weeks before screening; or start of treatment with such drugs within 2 weeks before screening;~* Parathyroidectomy and/or parathyroid intervention within 24 weeks before screening;~* Severe heart disease;~* Severe hepatic dysfunction;~* Uncontrolled hypertension and/or diabetes;~* Treatment with an investigational product (drug or medical device) in a clinical study or any study equivalent to clinical study within 12 weeks before screening;~* Primary hyperparathyroidism;~* Other conditions unfit for participation in this study at the discretion of the investigator or subinvestigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KHK7580 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed glioblastoma multiforme treated with temozolomide (200mg/m2) as monotherapy and patients with recurrent or progressive malignant glioma treated with temozolomide as monotherapy (200mg/m2).~* Male and female patients at least 18 of age.~* Non-pregnant, non-breast feeding female.~* Body mass index (weight/height²) in the range of 18.5 to 30 kg/m².~* Having given a written informed consent~Exclusion Criteria:~* Co-administration of sodium valproate~* Patients with (naso)gastric tubes~* Patients receiving 150 mg/m² and not eligible to the 200 mg/m² dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ped-TMZ (Type: EXPERIMENTAL): Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition.
- Temodal capsule (Type: ACTIVE_COMPARATOR): Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. The administration will take place around 8:00 a.m. followed with 240 mL of tap water, in sitting position and under fasting condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pancreatic Juice Diagnosis From Duodenum

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Common inclusion criterion~* Age is 18 years or older.~* Informed consent was obtained.~* Inclusion criterion for normal cohort~* An upper GI endoscopy is scheduled to check upper abdominal symptoms.~* No findings of pancreatic disorder as documented by CT or MRI or EUS~* Inclusion criterion for PC suspicious cohort~* A EUS or ERCP is scheduled to suspected pancreatic disorder.~Exclusion Criteria:~* Common exclusion criterion~* Severe cardiac disease~* Severe respiratory disease~* Bleeding disorders~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test subject (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Male and females aged 18 to 75~* Recipients of cadaveric, living unrelated or living related kidney transplant, treated with CsA-ME, with or without corticosteroids, as primary immunosuppression~Exclusion criteria:~* Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any organ, other than kidney.~* Patients with any known hypersensitivity to MPA, EC-MPS or other components of the formulation (e.g. lactose).~* Patients with thrombocytopenia (\< 75,000/mm3), with an absolute neutrophil count of \< 1,500/mm3, and/or leukocytopenia (\< 2,500/mm3), and/or hemoglobin \< 6 g/dL at Screening or Baseline.~Other inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Study Arms:
- EC MPS (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Current diagnosis of alcohol dependence, meeting at least 3 criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV)~* Recently completed alcohol detoxification and seeking treatment for alcohol dependence~* Women of childbearing potential must agree to use an approved method of contraception for study duration~Primary Exclusion Criteria:~* Pregnancy or lactation~* Evidence of hepatic failure including: ascites, bilirubin \>10% above upper limit of normal (ULN) and/or esophageal variceal disease~* Current dependence (within the past year) to benzodiazepines or cocaine, or current or history of opioid dependence according to DSM-IV criteria~* Use of any opioids and/or methadone within 14 days prior to the screening visit, or likely to require opioid therapy during the study period~* Previous enrollment in a VIVITROL clinical trial or previous VIVITROL experience~* Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-glycolide (PLG)~* Parole, probation, or pending legal proceedings having the potential for incarceration during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VIVITROL 380 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Female patients who meet the following criteria:~1. Patients satisfying the Rome III Diagnostic Criteria~2. Patients whose ≥25% of stools were loose or watery and \<25% of them were hard or lumpy stools~3. Patients who have abdominal pain or discomfort~4. Patients in whom after occurrence of IBS symptoms the following tests were conducted and in whom no organic changes were observed Pancolonoscopy or contrast enema~Exclusion Criteria:~Patients who meet any of the following criteria:~1. Patients with a history of surgical resection of the stomach,gallbladder, small intestine or large intestine~2. Patients with a history or current evidence of inflammatory bowel disease~3. Patients with a history or current evidence of colitis ischemic~4. Patients with concurrent infectious enteritis~5. Patients with concurrent hyperthyroidism or hypothyroidism~6. Patients with concurrent active peptic ulcer~7. Patients with other concurrent disease that may affect the digestive tract passage or large intestinal function or that is likely to interfere with proper assessment of IBS abdominal pain/discomfort

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Female Patients with D-IBS (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete